|
1
|
Cancer Genome Atlas Research Network.
Electronic address, . simpleAndrew_aguirre@dfci.harvard.edu;
Cancer Genome Atlas Research Network. Integrated Genomic
Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell.
32:185–203.e113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klein AP: Pancreatic cancer epidemiology:
Understanding the role of lifestyle and inherited risk factors. Nat
Rev Gastroenterol Hepatol. 18:493–502. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong
Y, Qian Y, Huang Q, Ni Q, Liu C and Yu X: Roles of CA19-9 in
pancreatic cancer: Biomarker, predictor and promoter. Biochim
Biophys Acta Rev Cancer. 1875:1884092021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carmicheal J, Patel A, Dalal V, Atri P,
Dhaliwal AS, Wittel UA, Malafa MP, Talmon G, Swanson BJ, Singh S,
et al: Elevating pancreatic cystic lesion stratification: Current
and future pancreatic cancer biomarker(s). Biochim Biophys Acta Rev
Cancer. 1873:1883182020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bestari MB, Joewono IR and Syam AF: A
quest for survival: a review of the early biomarkers of pancreatic
cancer and the most effective approaches at present. Biomolecules
14: 364. (doi: 10.3390/biom14030364). 2024. View Article : Google Scholar
|
|
7
|
Yang J and Xu R: Early screening and
diagnosis strategies of pancreatic cancer: A comprehensive review.
Cancer Commun (Lond). 41:1257–1274. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo
X, Wei Q, Wang J, Xiong H, Chen C, Xu B, et al: Exosome: Emerging
biomarker in breast cancer. Oncotarget. 8:41717–41733. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang
JH and Zhang SJ: Exosome biogenesis: Machinery, regulation, and
therapeutic implications in cancer. Mol Cancer. 21:2072022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Awadallah NS, Shroyer KR, Langer DA,
Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR and Shah
RJ: Detection of B7-H4 and p53 in pancreatic cancer: Potential role
as a cytological diagnostic adjunct. Pancreas. 36:200–206. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bausch D, Mino-Kenudson M, Fernández-Del
Castillo C, Warshaw AL, Kelly KA and Thayer SP: Plectin-1 is a
biomarker of malignant pancreatic intraductal papillary mucinous
neoplasms. J Gastrointest Surg. 13:1948–1954. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu W, Ma Y, Shankar S and Srivastava RK:
Role of SATB2 in human pancreatic cancer: Implications in
transformation and a promising biomarker. Oncotarget.
7:57783–57797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou CY, Dong YP, Sun X, Sui X, Zhu H,
Zhao YQ, Zhang YY, Mason C, Zhu Q and Han SX: High levels of serum
glypican-1 indicate poor prognosis in pancreatic ductal
adenocarcinoma. Cancer Med. 7:5525–5533. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Padden J, Ahrens M, Kälsch J, Bertram S,
Megger DA, Bracht T, Eisenacher M, Kocabayoglu P, Meyer HE, Sipos
B, et al: Immunohistochemical markers distinguishing
cholangiocellular carcinoma (CCC) from pancreatic ductal
adenocarcinoma (PDAC) discovered by proteomic analysis of
microdissected cells. Mol Cell Proteomics. 15:1072–1082. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herreros-Villanueva M and Bujanda L:
Non-invasive biomarkers in pancreatic cancer diagnosis: What we
need versus what we have. Ann Transl Med. 4:1342016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brezgyte G, Shah V, Jach D and
Crnogorac-Jurcevic T: Non-invasive biomarkers for earlier detection
of pancreatic Cancer-A comprehensive review. Cancers (Basel).
13:2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng H, Liang X, Liu B, Huang X, Shen Y,
Lin F, Chen J, Gao X, He H, Li W, et al: Exosomal miR-9-5p derived
from iPSC-MSCs ameliorates doxorubicin-induced cardiomyopathy by
inhibiting cardiomyocyte senescence. J Nanobiotechnology.
22:1952024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen YX and Cai Q: Plant Exosome-like
nanovesicles and their role in the innovative delivery of RNA
therapeutics. Biomedicines. 11:18062023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tamura R, Balabanova A, Frakes SA,
Bargmann A, Grimm J, Koch TH and Yin H: Photoactivatable prodrug of
doxazolidine targeting exosomes. J Med Chem. 62:1959–1970. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kreger BT, Johansen ER, Cerione RA and
Antonyak MA: The enrichment of survivin in exosomes from breast
cancer cells treated with paclitaxel promotes cell survival and
chemoresistance. Cancers. 8:1112016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melo SA, Luecke LB, Kahlert C, Fernandez
AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari
N, et al: Glypican-1 identifies cancer exosomes and detects early
pancreatic cancer. Nature. 523:177–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao X, Wu D, Ma X, Wang J, Hou W and
Zhang W: Exosomes as drug carriers for cancer therapy and
challenges regarding exosome uptake. Biomed Pharmacother.
128:1102372020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou X, Yan Y, Shen Y, Xu M and Xu W:
Exosomes: Emerging insights into the progression of pancreatic
cancer. Int J Biol Sci. 20:4098–4113. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qin C, Li T, Lin C, Zhao B, Li Z, Zhao Y
and Wang W: The systematic role of pancreatic cancer exosomes:
Distant communication, liquid biopsy and future therapy. Cancer
Cell Int. 24:2642024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Kleeff J and Sunami Y: Pancreatic
cancer cell- and cancer-associated fibroblast-derived exosomes in
disease progression, metastasis, and therapy. Discov Oncol.
15:2532024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Feng J, Wang Q, Zhao Y, Ding H,
Jiang K, Ji H, Tang Z and Dai R: Knowledge mapping and research
trends of exosomes in pancreatic cancer: A bibliometric analysis
and review (2013–2023). Front Oncol. 14:13624362024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trifylli EM, Kriebardis AG, Koustas E,
Papadopoulos N, Fortis SP, Tzounakas VL, Anastasiadi AT, Sarantis
P, Vasileiadi S, Tsagarakis A, et al: A current synopsis of the
emerging role of extracellular vesicles and Micro-RNAs in
pancreatic cancer: A Forward-Looking plan for diagnosis and
treatment. Int J Mol Sci. 25:34062024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sha G, Zhang W, Jiang Z, Zhao Q, Wang D
and Tang D: Exosomal non-coding RNA: A new frontier in diagnosing
and treating pancreatic cancer: A review. Int J Biol Macromol.
263:1301492024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Papadakos SP, Dedes N, Pergaris A, Gazouli
M and Theocharis S: Exosomes in the Treatment of Pancreatic Cancer:
A moonshot to PDAC treatment? Int J Mol Sci. 23:36202022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ariston Gabriel AN, Wang F, Jiao Q, Yvette
U, Yang X, Al-Ameri SA, Du L, Wang YS and Wang C: The involvement
of exosomes in the diagnosis and treatment of pancreatic cancer.
Mol Cancer. 19:1322020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang X, Lan H, Jin K and Qian J:
Pancreatic cancer and exosomes: Role in progression, diagnosis,
monitoring, and treatment. Front Oncol. 13:11495512023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bunduc S, Gede N, Váncsa S, Lillik V, Kiss
S, Juhász MF, Erőss B, Szakács Z, Gheorghe C, Mikó A and Hegyi P:
Exosomes as prognostic biomarkers in pancreatic ductal
adenocarcinoma-a systematic review and meta-analysis. Transl Res.
244:126–136. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu B, Chen Y, Peng M, Zheng JH and Zuo C:
Exploring the potential of exosomes in diagnosis and drug delivery
for pancreatic ductal adenocarcinoma. Int J Cancer. 152:110–122.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hsu SK, Jadhao M, Liao WT, Chang WT, Lin
IL and Chiu CC: The role of exosomes in pancreatic ductal
adenocarcinoma progression and their potential as biomarkers.
Cancers (Basel). 15:17762023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han L, Zhao Z, Yang K, Xin M, Zhou L, Chen
S, Zhou S, Tang Z, Ji H and Dai R: Application of exosomes in the
diagnosis and treatment of pancreatic diseases. Stem Cell Res Ther.
13:1532022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Doyle LM and Wang MZ: Overview of
extracellular vesicles, their origin, composition, purpose, and
methods for exosome isolation and analysis. Cells. 8:7272019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wortzel I, Dror S, Kenific CM and Lyden D:
Exosome-mediated metastasis: Communication from a distance. Dev
Cell. 49:347–360. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He C, Zheng S, Luo Y and Wang B: Exosome
theranostics: Biology and translational medicine. Theranostics.
8:237–255. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Duan SL, Fu WJ, Jiang YK, Peng LS, Ousmane
D, Zhang ZJ and Wang JP: Emerging role of exosome-derived
non-coding RNAs in tumor-associated angiogenesis of tumor
microenvironment. Front Mol Biosci. 10:12201932023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367:eaau69772020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pegtel DM and Gould SJ: Exosomes. Annu Rev
Biochem. 88:487–514. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dai X, Ye Y and He F: Emerging innovations
on exosome-based onco-therapeutics. Front Immunol. 13:8652452022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Skotland T, Hessvik NP, Sandvig K and
Llorente A: Exosomal lipid composition and the role of ether lipids
and phosphoinositides in exosome biology. J Lipid Res. 60:9–18.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mashouri L, Yousefi H, Aref AR, Ahadi AM,
Molaei F and Alahari SK: Exosomes: Composition, biogenesis, and
mechanisms in cancer metastasis and drug resistance. Mol Cancer.
18:752019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He C, Li L, Wang L, Meng W, Hao Y and Zhu
G: Exosome-mediated cellular crosstalk within the tumor
microenvironment upon irradiation. Cancer Biol Med. 18:21–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Peng H, Ji W, Zhao R, Yang J, Lu Z, Li Y
and Zhang X: Exosome: A significant nano-scale drug delivery
carrier. J Mater Chem B. 8:7591–7608. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Im H, Shao H, Weissleder R, Castro CM and
Lee H: Nano-plasmonic exosome diagnostics. Expert Rev Mol Diagn.
15:725–733. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hamzah RN, Alghazali KM, Biris AS and
Griffin RJ: Exosome traceability and cell source dependence on
composition and cell-cell cross talk. Int J Mol Sci. 22:53462021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kawamura S, Iinuma H, Wada K, Takahashi K,
Minezaki S, Kainuma M, Shibuya M, Miura F and Sano K:
Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21
in portal vein blood is a high-sensitive liquid biomarker for the
selection of high-risk pancreatic ductal adenocarcinoma patients. J
Hepatobiliary Pancreat Sci. 26:63–72. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu L, Wu LF and Deng FY: Exosome: An
emerging source of biomarkers for human diseases. Curr Mol Med.
19:387–394. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lobb RJ, Becker M, Wen SW, Wong CS,
Wiegmans AP, Leimgruber A and Möller A: Optimized exosome isolation
protocol for cell culture supernatant and human plasma. J Extracell
Vesicles. 4:270312015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tang YT, Huang YY, Zheng L, Qin SH, Xu XP,
An TX, Xu Y, Wu YS, Hu XM, Ping BH and Wang Q: Comparison of
isolation methods of exosomes and exosomal RNA from cell culture
medium and serum. Int J Mol Med. 40:834–844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vaswani K, Mitchell MD, Holland OJ, Qin
Koh Y, Hill RJ, Harb T, Davies PSW and Peiris H: A Method for the
isolation of exosomes from human and bovine milk. J Nutr Metab.
2019:57647402019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tayebi M, Zhou Y, Tripathi P,
Chandramohanadas R and Ai Y: Exosome purification and analysis
using a facile microfluidic hydrodynamic trapping device. Anal
Chem. 92:10733–10742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gonzalez H, Hagerling C and Werb Z: Roles
of the immune system in cancer: From tumor initiation to metastatic
progression. Genes Dev. 32:1267–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
He Z, Wang J, Zhu C, Xu J, Chen P, Jiang
X, Chen Y, Jiang J and Sun C: Exosome-derived FGD5-AS1 promotes
tumor-associated macrophage M2 polarization-mediated pancreatic
cancer cell proliferation and metastasis. Cancer Lett.
548:2157512022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang Y, Liu Y, Liu H and Tang WH:
Exosomes: Biogenesis, biologic function and clinical potential.
Cell Biosci. 9:192019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ,
Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, et al: The molecular
biology of pancreatic adenocarcinoma: Translational challenges and
clinical perspectives. Signal Transduct Target Ther. 6:2492021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kumari N and Choi SH: Tumor-associated
macrophages in cancer: Recent advancements in cancer
nanoimmunotherapies. J Exp Clin Cancer Res. 41:682022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Qian Y, Yin Y, Zheng X, Liu Z and Wang X:
Metabolic regulation of tumor-associated macrophage heterogeneity:
Insights into the tumor microenvironment and immunotherapeutic
opportunities. Biomark Res. 12:12024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mao X, Xu J, Wang W, Liang C, Hua J, Liu
J, Zhang B, Meng Q, Yu X and Shi S: Crosstalk between
cancer-associated fibroblasts and immune cells in the tumor
microenvironment: New findings and future perspectives. Mol Cancer.
20:1312021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pritchard A, Tousif S, Wang Y, Hough K,
Khan S, Strenkowski J, Chacko BK, Darley-Usmar VM and Deshane JS:
Lung tumor cell-derived exosomes promote M2 macrophage
polarization. Cells. 9:13032020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pan Y, Tang H, Li Q, Chen G and Li D:
Exosomes and their roles in the chemoresistance of pancreatic
cancer. Cancer Med. 11:4979–4988. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Papadakos SP, Machairas N, Stergiou IE,
Arvanitakis K, Germanidis G, Frampton AE and Theocharis S:
Unveiling the Yin-Yang balance of M1 and M2 macrophages in
hepatocellular carcinoma: Role of exosomes in tumor
microenvironment and immune modulation. Cells. 12:20362023.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang L, Li Z, Shen J, Liu Z, Liang J, Wu
X, Sun X and Wu Z: Exosome-like vesicles derived by Schistosoma
japonicum adult worms mediates M1 type immune-activity of
macrophage. Parasitol Res. 114:1865–1873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chehelgerdi M, Chehelgerdi M, Allela OQB,
Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M,
Viktor P, Lakshmaiya N, et al: Progressing nanotechnology to
improve targeted cancer treatment: Overcoming hurdles in its
clinical implementation. Mol Cancer. 22:1692023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cui X, Fu Q, Wang X, Xia P, Cui X, Bai X
and Lu Z: Molecular mechanisms and clinical applications of
exosomes in prostate cancer. Biomark Res. 10:562022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang J, Li S, Li L, Guo C, Yao J and Mi
S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Milane L, Singh A, Mattheolabakis G,
Suresh M and Amiji MM: Exosome mediated communication within the
tumor microenvironment. J Control Release. 219:278–294. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Khan MI and Alsayed R: Exosome-mediated
response to cancer therapy: Modulation of Epigenetic Machinery. Int
J Mol Sci. 23:62222022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
McAndrews KM, Xiao F, Chronopoulos A,
LeBleu VS, Kugeratski FG and Kalluri R: Exosome-mediated delivery
of CRISPR/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic
cancer. Life Sci Alliance. 4:e2020008752021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Su MJ, Aldawsari H and Amiji M: Pancreatic
cancer cell exosome-mediated macrophage reprogramming and the role
of MicroRNAs 155 and 125b2 transfection using nanoparticle delivery
systems. Sci Rep. 6:301102016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Caruso Bavisotto C, Cappello F, Macario
AJL, Conway de Macario E, Logozzi M, Fais S and Campanella C:
Exosomal HSP60: A potentially useful biomarker for diagnosis,
assessing prognosis, and monitoring response to treatment. Expert
Rev Mol Diagn. 17:815–822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dudeja V, Mujumdar N, Phillips P, Chugh R,
Borja-Cacho D, Dawra RK, Vickers SM and Saluja AK: Heat shock
protein 70 inhibits apoptosis in cancer cells through simultaneous
and independent mechanisms. Gastroenterology. 136:1772–1782. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shaashua L, Ben-Shmuel A, Pevsner-Fischer
M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown
LE, Zhang W, et al: BRCA mutational status shapes the stromal
microenvironment of pancreatic cancer linking clusterin expression
in cancer associated fibroblasts with HSF1 signaling. Nat Commun.
13:65132022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jin H, Liu P, Wu Y, Meng X, Wu M, Han J
and Tan X: Exosomal zinc transporter ZIP4 promotes cancer growth
and is a novel diagnostic biomarker for pancreatic cancer. Cancer
Sci. 109:2946–2956. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Castillo J, Bernard V, San Lucas FA,
Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM,
Huang J, et al: Surfaceome profiling enables isolation of
cancer-specific exosomal cargo in liquid biopsies from pancreatic
cancer patients. Ann Oncol. 29:223–229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang R, Loganathan S, Humphreys I and
Srivastava SK: Benzyl isothiocyanate-induced DNA damage causes G2/M
cell cycle arrest and apoptosis in human pancreatic cancer cells. J
Nutr. 136:2728–2734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ristorcelli E, Beraud E, Mathieu S,
Lombardo D and Verine A: Essential role of Notch signaling in
apoptosis of human pancreatic tumoral cells mediated by exosomal
nanoparticles. Int J Cancer. 125:1016–1026. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Huang J, Chen P, Liu K, Liu J, Zhou B, Wu
R, Peng Q, Liu ZX, Li C, Kroemer G, et al: CDK1/2/5 inhibition
overcomes IFNG-mediated adaptive immune resistance in pancreatic
cancer. Gut. 70:890–899. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hayes TK, Neel NF, Hu C, Gautam P, Chenard
M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, et al:
Long-term ERK inhibition in KRAS-mutant pancreatic cancer is
associated with MYC degradation and Senescence-like growth
suppression. Cancer Cell. 29:75–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li B, Cao Y, Sun M and Feng H: Expression,
regulation, and function of exosome-derived miRNAs in cancer
progression and therapy. FASEB J. 35:e219162021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sun W, Ren Y, Lu Z and Zhao X: The
potential roles of exosomes in pancreatic cancer initiation and
metastasis. Mol Cancer. 19:1352020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY,
Wang L and Zhan HX: Early detection of pancreatic cancer: Where are
we now and where are we going? Int J Cancer. 141:231–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhao C, Gao F, Weng S and Liu Q:
Pancreatic cancer and associated exosomes. Cancer Biomark.
20:357–367. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yan Y, Fu G and Ming L: Role of exosomes
in pancreatic cancer. Oncol Lett. 15:7479–7488. 2018.PubMed/NCBI
|
|
88
|
Wang X, Luo G, Zhang K, Cao J, Huang C,
Jiang T, Liu B, Su L and Qiu Z: Hypoxic tumor-derived exosomal
miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to
promote pancreatic cancer metastasis. Cancer Res. 78:4586–4598.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chiba M, Kubota S, Sato K and Monzen S:
Exosomes released from pancreatic cancer cells enhance angiogenic
activities via dynamin-dependent endocytosis in endothelial cells
in vitro. Sci Rep. 8:119722018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li J, Li Z, Jiang P, Peng M, Zhang X, Chen
K, Liu H, Bi H, Liu X and Li X: Circular RNA IARS (circ-IARS)
secreted by pancreatic cancer cells and located within exosomes
regulates endothelial monolayer permeability to promote tumor
metastasis. J Exp Clin Cancer Res. 37:1772018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhou X, Zhong F, Yan Y, Wu S, Wang H, Liu
J, Li F, Cui D and Xu M: Pancreatic cancer cell-derived exosomes
promote lymphangiogenesis by downregulating ABHD11-AS1 expression.
Cancers (Basel). 14:46122022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li M, Zhou J, Zhang Z, Li J, Wang F, Ma L,
Tian X, Mao Z and Yang Y: Exosomal miR-485-3p derived from
pancreatic ductal epithelial cells inhibits pancreatic cancer
metastasis through targeting PAK1. Chin Med J. 135:2326–2337. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Di Pace AL, Pelosi A, Fiore PF, Tumino N,
Besi F, Quatrini L, Santopolo S, Vacca P and Moretta L: MicroRNA
analysis of Natural Killer cell-derived exosomes: The microRNA
let-7b-5p is enriched in exosomes and participates in their
anti-tumor effects against pancreatic cancer cells. Oncoimmunology.
12:22210812023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sun H, Shi K, Qi K, Kong H, Zhang J, Dai
S, Ye W, Deng T, He Q and Zhou M: Natural killer cell-derived
exosomal miR-3607-3p inhibits pancreatic cancer progression by
targeting IL-26. Front Immunol. 10:28192019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yin Z, Zhou Y, Ma T, Chen S, Shi N, Zou Y,
Hou B and Zhang C: Down-regulated lncRNA SBF2-AS1 in M2
macrophage-derived exosomes elevates miR-122-5p to restrict XIAP,
thereby limiting pancreatic cancer development. J Cell Mol Med.
24:5028–5038. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Xie X, Ji J, Chen X, Xu W, Chen H, Zhu S,
Wu J, Wu Y, Sun Y, Sai W, et al: Human umbilical cord mesenchymal
stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress
pancreatic ductal cell carcinoma by inhibiting Galectin-3. Clin
Transl Oncol. 24:517–531. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Torphy RJ, Fujiwara Y and Schulick RD:
Pancreatic cancer treatment: Better, but a long way to go. Surg
Today. 50:1117–1125. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhao Z and Liu W: Pancreatic cancer: A
review of risk factors, diagnosis, and treatment. Technol Cancer
Res Treat. 19:15330338209621172020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Cai J, Chen H, Lu M, Zhang Y, Lu B, You L,
Zhang T, Dai M and Zhao Y: Advances in the epidemiology of
pancreatic cancer: Trends, risk factors, screening, and prognosis.
Cancer Lett. 520:1–11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Loveday BPT, Lipton L and Thomson BN:
Pancreatic cancer: An update on diagnosis and management. Aust J
Gen Pract. 48:826–831. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Scarà S, Bottoni P and Scatena R: CA 19-9:
Biochemical and clinical aspects. Adv Exp Med Biol. 867:247–260.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Nakamura K, Zhu Z, Roy S, Jun E, Han H,
Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, et al:
An Exosome-based transcriptomic signature for noninvasive, early
detection of patients with pancreatic ductal adenocarcinoma: A
multicenter cohort study. Gastroenterology. 163:1252–1266.e2. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Tempero MA, Malafa MP, Al-Hawary M,
Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B,
Del Chiaro M, et al: Pancreatic adenocarcinoma, version 2.2021,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 19:439–457. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hu ZI and O'Reilly EM: Therapeutic
developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol.
21:7–24. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lupo F, Pezzini F, Pasini D, Fiorini E,
Adamo A, Veghini L, Bevere M, Frusteri C, Delfino P, D'agosto S, et
al: Axon guidance cue SEMA3A promotes the aggressive phenotype of
basal-like PDAC. Gut. 73:1321–1335. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Reese M and Dhayat SA: Small extracellular
vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms
and clinical implications. J Hematol Oncol. 14:1412021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ran Z, Wu S, Ma Z, Chen X, Liu J and Yang
J: Advances in exosome biomarkers for cervical cancer. Cancer Med.
11:4966–4978. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yuan Y, Li H, Pu W, Chen L, Guo D, Jiang
H, He B, Qin S, Wang K, Li N, et al: Cancer metabolism and tumor
microenvironment: Fostering each other? Sci China Life Sci.
65:236–279. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wu L, Zhou WB, Zhou J, Wei Y, Wang HM, Liu
XD, Chen XC, Wang W, Ye L, Yao LC, et al: Circulating exosomal
microRNAs as novel potential detection biomarkers in pancreatic
cancer. Oncol Lett. 20:1432–1440. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Condrat CE, Thompson DC, Barbu MG, Bugnar
OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM and Voinea SC: miRNAs
as biomarkers in disease: Latest findings regarding their role in
diagnosis and prognosis. Cells. 9:2762020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ouyang H, Gore J, Deitz S and Korc M:
microRNA-10b enhances pancreatic cancer cell invasion by
suppressing TIP30 expression and promoting EGF and TGF-β actions.
Oncogene. 33:4664–4674. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H,
Fang X and Zhang X: Exosomes as a new frontier of cancer liquid
biopsy. Mol Cancer. 21:562022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
He C, Li L, Wang L, Meng W, Hao Y and Zhu
G: Exosome-mediated cellular crosstalk within the tumor
microenvironment upon irradiation. Cancer Biol Med. 18:21–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jiang Z, Wang H, Mou Y, Li L and Jin W:
Functions and clinical applications of exosomes in pancreatic
cancer. Mol Biol Rep. 49:11037–11048. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ashrafizadeh M, Rabiee N, Kumar AP, Sethi
G, Zarrabi A and Wang Y: Long noncoding RNAs (lncRNAs) in
pancreatic cancer progression. Drug Discov Today. 27:2181–2198.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Kato S and Honda K: Use of biomarkers and
imaging for early detection of pancreatic cancer. Cancers (Basel).
12:19652020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhao X, Ren Y and Lu Z: Potential
diagnostic and therapeutic roles of exosomes in pancreatic cancer.
Biochim Biophys Acta Rev Cancer. 1874:1884142020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Frampton AE, Prado MM, López-Jiménez E,
Fajardo-Puerta AB, Jawad ZAR, Lawton P, Giovannetti E, Habib NA,
Castellano L, Stebbing J, et al: Glypican-1 is enriched in
circulating-exosomes in pancreatic cancer and correlates with tumor
burden. Oncotarget. 9:19006–19013. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Marin AM, Mattar SB, Amatuzzi RF, Chammas
R, Uno M, Zanette DL and Aoki MN: Plasma exosome-derived microRNAs
as potential diagnostic and prognostic biomarkers in brazilian
pancreatic cancer patients. Biomolecules. 12:7692022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang L, Wu J, Ye N, Li F, Zhan H, Chen S
and Xu J: Plasma-derived exosome MiR-19b acts as a diagnostic
marker for pancreatic cancer. Front Oncol. 11:7391112021.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Nakamura S, Sadakari Y, Ohtsuka T, Okayama
T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, et
al: Pancreatic Juice exosomal MicroRNAs as biomarkers for detection
of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 26:2104–2111.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chen SL, Ma M, Yan L, Xiong SH, Liu Z, Li
S, Liu T, Shang S, Zhang YY, Zeng H, et al: Clinical significance
of exosomal miR-1231 in pancreatic cancer]. Zhonghua Zhong Liu Za
Zhi. 41:46–49. 2019.(In Chinese). PubMed/NCBI
|
|
124
|
Corrigendum to Serum exosomal miR-451a
acts as a candidate marker for pancreatic cancer. Int J Biol
Markers. 37:2242022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y,
Qian L, Zhao J, Zong H, Kang B, et al: Plasma extracellular vesicle
long RNA profiling identifies a diagnostic signature for the
detection of pancreatic ductal adenocarcinoma. Gut. 69:540–550.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hong L, Xu L, Jin L, Xu K, Tang W, Zhu Y,
Qiu X and Wang J: Exosomal circular RNA hsa_circ_0006220, and
hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic
cancer. J Clin Lab Anal. 36:e244472022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yadav DK, Bai X, Yadav RK, Singh A, Li G,
Ma T, Chen W and Liang T: Liquid biopsy in pancreatic cancer: The
beginning of a new era. Oncotarget. 9:26900–26933. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Allenson K, Castillo J, San Lucas FA,
Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ,
et al: High prevalence of mutant KRAS in circulating
exosome-derived DNA from early-stage pancreatic cancer patients.
Ann Oncol. 28:741–747. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Mizukami K, Iwasaki Y, Kawakami E, Hirata
M, Kamatani Y, Matsuda K, Endo M, Sugano K, Yoshida T, Murakami Y,
et al: Genetic characterization of pancreatic cancer patients and
prediction of carrier status of germline pathogenic variants in
cancer-predisposing genes. EBioMedicine. 60:1030332020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lai E, Ziranu P, Spanu D, Dubois M, Pretta
A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, et al:
BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer.
125:1321–1332. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Moutinho-Ribeiro P, Adem B, Batista I,
Silva M, Silva S, Ruivo CF, Morais R, Peixoto A, Coelho R,
Costa-Moreira P, et al: Exosomal glypican-1 discriminates
pancreatic ductal adenocarcinoma from chronic pancreatitis. Dig
Liver Dis. 54:871–877. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yoshizawa N, Sugimoto K, Tameda M, Inagaki
Y, Ikejiri M, Inoue H, Usui M, Ito M and Takei Y:
miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic
biomarker for pancreatic ductal adenocarcinoma. Oncol Lett.
19:2677–2684. 2020.PubMed/NCBI
|
|
133
|
Xie Z, Gao Y, Ho C, Li L, Jin C, Wang X,
Zou C, Mao Y, Wang X, Li Q, et al: Exosome-delivered CD44v6/C1QBP
complex drives pancreatic cancer liver metastasis by promoting
fibrotic liver microenvironment. Gut. 71:568–579. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ishihara M, Kageyama S, Miyahara Y,
Ishikawa T, Ueda S, Soga N, Naota H, Mukai K, Harada N, Ikeda H and
Shiku H: MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and
co-expression relationships in solid tumours. BMC Cancer.
20:6062020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Hashimoto K, Nishimura S, Ito T and Akagi
M: Clinicopathological assessment of cancer/testis antigens
NY-ESO-1 and MAGE-A4 in highly aggressive soft tissue sarcomas.
Diagnostics (Basel). 12:7332022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wu H, Chen X, Ji J, Zhou R, Liu J, Ni W,
Qu L, Ni H, Ni R, Bao B and Xiao M: Progress of exosomes in the
diagnosis and treatment of pancreatic cancer. Gene Test Mol
Biomarkers. 23:215–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Xu M, Hu W, Liu Z, Xia J, Chen S, Wang PG
and Yang S: Glycoproteomic bioanalysis of exosomes by LC-MS for
early diagnosis of pancreatic cancer. Bioanalysis. 13:861–864.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhao Y, Tang J, Jiang K, Liu SY, Aicher A
and Heeschen C: Liquid biopsy in pancreatic cancer-Current
perspective and future outlook. Biochim Biophys Acta Rev Cancer.
1878:1888682023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Raufi AG, May MS, Hadfield MJ, Seyhan AA
and El-Deiry WS: Advances in Liquid Biopsy Technology and
Implications for Pancreatic Cancer. Int J Mol Sci. 24:42382023.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Haeberle L, Schramm M, Goering W, Frohn L,
Driescher C, Hartwig W, Preissinger-Heinzel HK, Beyna T, Neuhaus H,
Fuchs K, et al: Molecular analysis of cyst fluids improves the
diagnostic accuracy of pre-operative assessment of pancreatic
cystic lesions. Sci Rep. 11:29012021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Karunakaran M and Barreto SG: Surgery for
pancreatic cancer: Current controversies and challenges. Future
Oncol. 17:5135–5162. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Strobel O and Neoptolemos J: Optimizing
the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol.
16:11–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Yoshida K, Iwashita T, Uemura S, Maruta A,
Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T and Shimizu M: A
multicenter prospective phase II study of first-line modified
FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget.
8:111346–111355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Pajewska M, Partyka O, Czerw A, Deptała A,
Cipora E, Gąska I, Wojtaszek M, Sygit K, Sygit M, Krzych-Fałta E,
et al: Management of metastatic pancreatic Cancer-comparison of
global guidelines over the last 5 years. Cancers (Basel).
15:44002023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Strickler JH, Satake H, George TJ, Yaeger
R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler
AL, Falchook GS, et al: Sotorasib in KRAS p.G12C-mutated advanced
pancreatic cancer. N Engl J Med. 388:33–43. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance Olaparib for Germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Ijichi H, Chytil A, Gorska AE, Aakre ME,
Fujitani Y, Fujitani S, Wright CV and Moses HL: Aggressive
pancreatic ductal adenocarcinoma in mice caused by
pancreas-specific blockade of transforming growth factor-beta
signaling in cooperation with active Kras expression. Genes Dev.
20:3147–3160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wang Z, Ali S, Banerjee S, Bao B, Li Y,
Azmi AS, Korc M and Sarkar FH: Activated K-Ras and INK4a/Arf
deficiency promote aggressiveness of pancreatic cancer by induction
of EMT consistent with cancer stem cell phenotype. J Cell Physiol.
228:556–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Pirlog R and Calin GA: KRAS mutations as
essential promoters of lymphangiogenesis via extracellular vesicles
in pancreatic cancer. J Clin Invest. 132:e1614542022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Chang WH, Nguyen TT, Hsu CH, Bryant KL,
Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA and Antonyak MA:
KRAS-dependent cancer cells promote survival by producing exosomes
enriched in Survivin. Cancer Lett. 517:66–77. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wang-Gillam A, Li CP, Bodoky G, Dean A,
Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et
al: Nanoliposomal irinotecan with fluorouracil and folinic acid in
metastatic pancreatic cancer after previous gemcitabine-based
therapy (NAPOLI-1): A global, randomised, open-label, phase 3
trial. Lancet. 387:545–557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ahmad SA, Duong M, Sohal DPS, Gandhi NS,
Beg MS, Wang-Gillam A, Wade JL III, Chiorean EG, Guthrie KA, Lowy
AM, et al: Surgical outcome results from SWOG S1505: A randomized
clinical trial of mFOLFIRINOX versus Gemcitabine/Nab-paclitaxel for
perioperative treatment of resectable pancreatic ductal
adenocarcinoma. Ann Surg. 272:481–486. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kunzmann V, Siveke JT, Algül H, Goekkurt
E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann
F, et al: Nab-paclitaxel plus gemcitabine versus nab-paclitaxel
plus gemcitabine followed by FOLFIRINOX induction chemotherapy in
locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): A
multicentre, randomised, phase 2 trial. Lancet Gastroenterol
Hepatol. 6:128–138. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Pitt JM, André F, Amigorena S, Soria JC,
Eggermont A, Kroemer G and Zitvogel L: Dendritic cell-derived
exosomes for cancer therapy. J Clin Invest. 126:1224–1232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Veerman RE, Güçlüler Akpinar G, Eldh M and
Gabrielsson S: Immune Cell-derived extracellular vesicles-functions
and therapeutic applications. Trends Mol Med. 25:382–394. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhao Y, Liu T and Zhou M:
Immune-cell-derived exosomes for cancer therapy. Mol Pharm.
19:3042–3056. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhao LX, Zhang K, Shen BB and Li JN:
Mesenchymal stem cell-derived exosomes for gastrointestinal cancer.
World J Gastrointest Oncol. 13:1981–1996. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen
Q, Zhang Y, Lu Y, Ding X and Jiang C: Bone marrow mesenchymal stem
cells-derived exosomes for penetrating and targeted chemotherapy of
pancreatic cancer. Acta Pharma Sin B. 10:1563–1575. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zhang L, Xiang J, Zhang F, Liu L and Hu C:
MSCs can be a double-edged sword in tumorigenesis. Front Oncol.
12:10479072022. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Whiteside TL: Exosome and mesenchymal stem
cell cross-talk in the tumor microenvironment. Semin Immunol.
35:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Ha DH, Kim HK, Lee J, Kwon HH, Park GH,
Yang SH, Jung JY, Choi H, Lee JH, Sung S, et al: Mesenchymal
Stem/stromal Cell-derived exosomes for immunomodulatory
therapeutics and skin regeneration. Cells. 9:11572020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi
H, Qian X, Wu M, Ji K, Zhao Y, et al: Umbilical Cord-derived
mesenchymal stem cell-derived exosomal MicroRNAs suppress
myofibroblast differentiation by inhibiting the transforming growth
factor-β/SMAD2 pathway during wound healing. Stem Cells Transl Med.
5:1425–1439. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhang Y, Hao Z, Wang P, Xia Y, Wu J, Xia
D, Fang S and Xu S: Exosomes from human umbilical cord mesenchymal
stem cells enhance fracture healing through HIF-1α-mediated
promotion of angiogenesis in a rat model of stabilized fracture.
Cell Prolif. 52:e125702019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Eldaly AS, Mashaly SM, Fouda E, Emam OS,
Aglan A, Abuasbeh J, Khurana A, Hamdar H and Fath AR: Systemic
anti-inflammatory effects of mesenchymal stem cells in burn: A
systematic review of animal studies. J Clin Transl Res. 8:276–291.
2022.PubMed/NCBI
|
|
167
|
Xu X, Yin F, Guo M, Gan G, Lin G, Wen C,
Wang J, Song P, Wang J, Qi ZQ and Zhong CQ: Quantitative proteomic
analysis of exosomes from umbilical cord mesenchymal stem cells and
rat bone marrow stem cells. Proteomics. 23:e22002042023. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Liu M, Yang Y, Zhao B, Yang Y, Wang J,
Shen K, Yang X, Hu D, Zheng G and Han J: Exosomes derived from
Adipose-derived mesenchymal stem cells ameliorate Radiation-induced
brain injury by activating the SIRT1 pathway. Front Cell Dev Biol.
9:6937822021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Shenoda BB and Ajit SK: Modulation of
immune responses by exosomes derived from Antigen-presenting cells.
Clin Med Insights Pathol. 9 (Suppl 1):S1–S8. 2016.PubMed/NCBI
|
|
170
|
Zaidi N, Soban M, Chen F, Kinkead H,
Mathew J, Yarchoan M, Armstrong TD, Haider S and Jaffee EM: Role of
in silico structural modeling in predicting immunogenic neoepitopes
for cancer vaccine development. JCI Insight. 5:e1369912020.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Yadav SS and Narayan G: Role of ROBO4
signalling in developmental and pathological angiogenesis. Biomed
Res Int. 2014:6830252014. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Xu Y, Li WL, Fu L, Gu F and Ma YJ:
Slit2/Robo1 signaling in glioma migration and invasion. Neurosci
Bull. 26:474–478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Wang L, Yang L, Zhuang T and Shi X:
Tumor-derived exosomal miR-29b reduces angiogenesis in pancreatic
cancer by silencing ROBO1 and SRGAP2. J Immunol Res.
2022:47693852022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sun X, Zhang Y, Li B and Yang H: MTA1
promotes the invasion and migration of pancreatic cancer cells
potentially through the HIF-α/VEGF pathway. J Recept Signal
Transduct Res. 38:352–358. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Lee JK, Park SR, Jung BK, Jeon YK, Lee YS,
Kim MK, Kim YG, Jang JY and Kim CW: Exosomes derived from
mesenchymal stem cells suppress angiogenesis by down-regulating
VEGF expression in breast cancer cells. PLoS One. 8:e842562013.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Pakravan K, Babashah S, Sadeghizadeh M,
Mowla SJ, Mossahebi-Mohammadi M, Ataei F, Dana N and Javan M:
MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes
suppresses in vitro angiogenesis through modulating the
mTOR/HIF-1α/VEGF signaling axis in breast cancer cells. Cell Oncol
(Dordr). 40:457–470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Yang E, Wang X, Gong Z, Yu M, Wu H and
Zhang D: Exosome-mediated metabolic reprogramming: The emerging
role in tumor microenvironment remodeling and its influence on
cancer progression. Signal Transduct Target Ther. 5:2422020.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Ye M, Huang X, Wu Q and Liu F: Senescent
stromal cells in the tumor microenvironment: Victims or
accomplices? Cancers (Basel). 15:19272023. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang
Q, Du J, Liu L, Li Y and Bai Y: Stromal cells in the tumor
microenvironment: Accomplices of tumor progression? Cell Death Dis.
14:5872023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Dai X, Xie Y and Dong M: Cancer-associated
fibroblasts derived extracellular vesicles promote angiogenesis of
colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis.
Cancer Biol Ther. 23:76–88. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Qin Y, Liu X, Pan L, Zhou R and Zhang X:
Long noncoding RNA MIR155HG facilitates pancreatic cancer
progression through negative regulation of miR-802. J Cell Biochem.
120:17926–17934. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Ren Y, Jia HH, Xu YQ, Zhou X, Zhao XH,
Wang YF, Song X, Zhu ZY, Sun T, Dou Y, et al: Paracrine and
epigenetic control of CAF-induced metastasis: The role of HOTAIR
stimulated by TGF-ß1 secretion. Mol Cancer. 17:52018. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Sansone P, Savini C, Kurelac I, Chang Q,
Amato LB, Strillacci A, Stepanova A, Iommarini L, Mastroleo C, Daly
L, et al: Packaging and transfer of mitochondrial DNA via exosomes
regulate escape from dormancy in hormonal therapy-resistant breast
cancer. Proc Natl Acad Sci USA. 114:E9066–E9075. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Achreja A, Zhao H, Yang L, Yun TH, Marini
J and Nagrath D: Exo-MFA-A 13C metabolic flux analysis framework to
dissect tumor microenvironment-secreted exosome contributions
towards cancer cell metabolism. Metab Eng. 43:156–172. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y,
Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, et
al: Exosome transfer from stromal to breast cancer cells regulates
therapy resistance pathways. Cell. 159:499–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Duong MN, Geneste A, Fallone F, Li X,
Dumontet C and Muller C: The fat and the bad: Mature adipocytes,
key actors in tumor progression and resistance. Oncotarget.
8:57622–57641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Frisbie L, Buckanovich RJ and Coffman L:
Carcinoma-associated mesenchymal stem/stromal cells: Architects of
the pro-tumorigenic tumor microenvironment. Stem Cells. 40:705–715.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Habanjar O, Diab-Assaf M, Caldefie-Chezet
F and Delort L: The impact of obesity, adipose tissue, and tumor
microenvironment on macrophage polarization and metastasis. Biology
(Basel). 11:3392022.PubMed/NCBI
|
|
189
|
Li B, Liu S, Yang Q, Li Z, Li J, Wu J, Sun
S, Xu Z, Sun S and Wu Q: Macrophages in tumor-associated adipose
microenvironment accelerate tumor progression. Adv Biol (Weinh).
7:e22001612023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Wen D, Liang T, Chen G, Li H, Wang Z, Wang
J, Fu R, Han X, Ci T, Zhang Y, et al: Adipocytes encapsulating
telratolimod recruit and polarize Tumor-Associated macrophages for
cancer immunotherapy. Adv Sci (Weinh). 10:e22060012023. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Masuda T, Fukuda A, Yamakawa G, Omatsu M,
Namikawa M, Sono M, Fukunaga Y, Nagao M, Araki O, Yoshikawa T, et
al: Pancreatic RECK inactivation promotes cancer formation,
epithelial-mesenchymal transition, and metastasis. J Clin Invest.
133:e1618472023. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Träger MM and Dhayat SA: Epigenetics of
epithelial-to-mesenchymal transition in pancreatic carcinoma. Int J
Cancer. 141:24–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Iwamoto C, Ohuchida K, Shinkawa T, Okuda
S, Otsubo Y, Okumura T, Sagara A, Koikawa K, Ando Y, Shindo K, et
al: Bone marrow-derived macrophages converted into
cancer-associated fibroblast-like cells promote pancreatic cancer
progression. Cancer Lett. 512:15–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Padoan A, Plebani M and Basso D:
Inflammation and pancreatic cancer: Focus on metabolism, cytokines,
and immunity. Int J Mol Sci. 20:6762019. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Malinova A, Veghini L, Real FX and Corbo
V: Cell lineage infidelity in PDAC progression and therapy
resistance. Front Cell Dev Biol. 9:7952512021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Chou CW, Huang YK, Kuo TT, Liu JP and Sher
YP: An overview of ADAM9: Structure, Activation, and regulation in
human diseases. Int J Mol Sci. 21:77902020. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Shang S, Wang J, Chen S, Tian R, Zeng H,
Wang L, Xia M, Zhu H and Zuo C: Exosomal miRNA-1231 derived from
bone marrow mesenchymal stem cells inhibits the activity of
pancreatic cancer. Cancer Med. 8:7728–7740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Yao X, Mao Y, Wu D, Zhu Y, Lu J, Huang Y,
Guo Y, Wang Z, Zhu S, Li X and Lu Y: Exosomal circ_0030167 derived
from BM-MSCs inhibits the invasion, migration, proliferation and
stemness of pancreatic cancer cells by sponging miR-338-5p and
targeting the Wif1/Wnt8/β-catenin axis. Cancer Lett. 512:38–50.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan
Y, Wang M, Zhu W, Qian H, Xu W, et al: Exosomes derived from human
mesenchymal stem cells confer drug resistance in gastric cancer.
Cell Cycle. 14:2473–2483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Gomis RR and Gawrzak S: Tumor cell
dormancy. Mol Oncol. 11:62–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Haider MT, Smit DJ and Taipaleenmäki H:
The Endosteal niche in breast cancer bone metastasis. Front Oncol.
10:3352020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Ono M, Kosaka N, Tominaga N, Yoshioka Y,
Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K and Ochiya
T: Exosomes from bone marrow mesenchymal stem cells contain a
microRNA that promotes dormancy in metastatic breast cancer cells.
Sci Signal. 7:ra632014. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Yang Y, Bucan V, Baehre H, von der Ohe J,
Otte A and Hass R: Acquisition of new tumor cell properties by
MSC-derived exosomes. Int J Oncol. 47:244–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Fu R, Shao Q, Yang B, Chen Y, Ye Q, Chen X
and Zhu J: MiR-520a-5p/PPP5C regulation pattern is identified as
the key to gemcitabine resistance in pancreatic cancer. Front
Oncol. 12:9034842022. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Fan J, Wei Q, Koay EJ, Liu Y, Ning B,
Bernard PW, Zhang N, Han H, Katz MH, Zhao Z and Hu Y:
Chemoresistance transmission via exosome-Mediated EphA2 transfer in
pancreatic cancer. Theranostics. 8:5986–5994. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Huang L, Rong Y, Tang X, Yi K, Qi P, Hou
J, Liu W, He Y, Gao X, Yuan C and Wang F: Engineered exosomes as an
in situ DC-primed vaccine to boost antitumor immunity in breast
cancer. Mol Cancer. 21:452022. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Tang W, Xia M, Liao Y, Fang Y, Wen G and
Zhong J: Exosomes in triple negative breast cancer: From bench to
bedside. Cancer Lett. 527:1–9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Scavo MP, Depalo N, Tutino V, De Nunzio V,
Ingrosso C, Rizzi F, Notarnicola M, Curri ML and Giannelli G:
Exosomes for diagnosis and therapy in gastrointestinal cancers. Int
J Mol Sci. 21:3672020. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Agrawal AK, Aqil F, Jeyabalan J, Spencer
WA, Beck J, Gachuki BW, Alhakeem SS, Oben K, Munagala R, Bondada S
and Gupta RC: Milk-derived exosomes for oral delivery of
paclitaxel. Nanomedicine. 13:1627–1636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Lux A, Kahlert C, Grützmann R and Pilarsky
C: c-Met and PD-L1 on circulating exosomes as diagnostic and
prognostic markers for pancreatic cancer. Int J Mol Sci.
20:33052019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Sakaue T, Koga H, Iwamoto H, Nakamura T,
Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, et al:
Glycosylation of ascites-derived exosomal CD133: A potential
prognostic biomarker in patients with advanced pancreatic cancer.
Med Mol Morphol. 52:198–208. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Takahasi K, Iinuma H, Wada K, Minezaki S,
Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F and Sano K:
Usefulness of exosome-encapsulated microRNA-451a as a minimally
invasive biomarker for prediction of recurrence and prognosis in
pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci.
25:155–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Wei Q, Li Z, Feng H and Ren L: Serum
exosomal EphA2 is a prognostic biomarker in patients with
pancreatic cancer. Cancer Manag Res. 13:3675–3683. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Chen D, Wu X, Xia M, Wu F, Ding J, Jiao Y,
Zhan Q and An F: Upregulated exosomic miR-23b-3p plays regulatory
roles in the progression of pancreatic cancer. Oncol Rep.
38:2182–2188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Li Z, Tao Y, Wang X, Jiang P, Li J, Peng
M, Zhang X, Chen K, Liu H, Zhen P, et al: Tumor-secreted exosomal
miR-222 promotes tumor progression via regulating P27 expression
and Re-localization in pancreatic cancer. Cell Physiol Biochem.
51:610–629. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu
W, Wang D and Lou W: Exosomal miRNA-106b from cancer-associated
fibroblast promotes gemcitabine resistance in pancreatic cancer.
Exp Cell Res. 383:1115432019. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Richards KE, Zeleniak AE, Fishel ML, Wu J,
Littlepage LE and Hill R: Cancer-associated fibroblast exosomes
regulate survival and proliferation of pancreatic cancer cells.
Oncogene. 36:1770–1778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Mikamori M, Yamada D, Eguchi H, Hasegawa
S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K,
et al: MicroRNA-155 controls exosome synthesis and promotes
gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci
Rep. 7:423392017. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Batista IA and Melo SA: Exosomes and the
future of immunotherapy in pancreatic cancer. Int J Mol Sci.
20:5672019. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Yin Z, Ma T, Huang B, Lin L, Zhou Y, Yan
J, Zou Y and Chen S: Macrophage-derived exosomal microRNA-501-3p
promotes progression of pancreatic ductal adenocarcinoma through
the TGFBR3-mediated TGF-β signaling pathway. J Exp Clin Cancer Res.
38:3102019. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Zhou W, Zhou Y, Chen X, Ning T, Chen H,
Guo Q, Zhang Y, Liu P, Zhang Y, Li C, et al: Pancreatic
cancer-targeting exosomes for enhancing immunotherapy and
reprogra-mming tumor microenvironment. Biomaterials.
268:1205462021. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Li YJ, Wu JY, Wang JM, Hu XB, Cai JX and
Xiang DX: Gemcitabine loaded autologous exosomes for effective and
safe chemotherapy of pancreatic cancer. Acta Biomater. 101:519–530.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Kamerkar S, LeBleu VS, Sugimoto H, Yang S,
Ruivo CF, Melo SA, Lee JJ and Kalluri R: Exosomes facilitate
therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Nature. 546:498–503. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Xiao L, Erb U, Zhao K, Hackert T and
Zöller M: Efficacy of vaccination with tumor-exosome loaded
dendritic cells combined with cytotoxic drug treatment in
pancreatic cancer. Oncoimmunology. 6:e13190442017. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Jang Y and Kim H, Yoon S, Lee H, Hwang J,
Jung J, Chang JH, Choi J and Kim H: Exosome-based photoacoustic
imaging guided photodynamic and immunotherapy for the treatment of
pancreatic cancer. J Control Release. 330:293–304. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Que RS, Lin C, Ding GP, Wu ZR and Cao LP:
Increasing the immune activity of exosomes: The effect of
miRNA-depleted exosome proteins on activating dendritic
cell/cytokine-induced killer cells against pancreatic cancer. J
Zhejiang Univ Sci B. 17:352–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Duan L, Xu L, Xu X, Qin Z, Zhou X, Xiao Y,
Liang Y and Xia J: Exosome-mediated delivery of gene vectors for
gene therapy. Nanoscale. 13:1387–1397. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Moon B and Chang S: Exosome as a delivery
vehicle for cancer therapy. Cells. 11:3162022. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Arrighetti N, Corbo C, Evangelopoulos M,
Pastò A, Zuco V and Tasciotti E: Exosome-like nanovectors for drug
delivery in cancer. Curr Med Chem. 26:6132–6148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Liang Y, Duan L, Lu J and Xia J:
Engineering exosomes for targeted drug delivery. Theranostics.
11:3183–3195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Guimarães D, Cavaco-Paulo A and Nogueira
E: Design of liposomes as drug delivery system for therapeutic
applications. Int J Pharm. 601:1205712021. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Lamichhane TN, Jeyaram A, Patel DB,
Parajuli B, Livingston NK, Arumugasaamy N, Schardt JS and Jay SM:
Oncogene knockdown via active loading of small RNAs into
extracellular vesicles by sonication. Cell Mol Bioeng. 9:315–324.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Zuo L, Tao H, Xu H, Li C, Qiao G, Guo M,
Cao S, Liu M and Lin X: Exosomes-coated miR-34a displays potent
antitumor activity in pancreatic cancer both in vitro and in vivo.
Drug Des Devel Ther. 14:3495–3507. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Ding Y, Cao F, Sun H, Wang Y, Liu S, Wu Y,
Cui Q, Mei W and Li F: Exosomes derived from human umbilical cord
mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit
pancreatic ductal adenocarcinoma progression. Cancer Lett.
442:351–361. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Duan H, Liu Y, Gao Z and Huang W: Recent
advances in drug delivery systems for targeting cancer stem cells.
Acta Pharm Sin B. 11:55–70. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Guo G, Tan Z, Liu Y, Shi F and She J: The
therapeutic potential of stem cell-derived exosomes in the
ulcerative colitis and colorectal cancer. Stem Cell Res Ther.
13:1382022. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Pascucci L, Coccè V, Bonomi A, Ami D,
Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM,
et al: Paclitaxel is incorporated by mesenchymal stromal cells and
released in exosomes that inhibit in vitro tumor growth: A new
approach for drug delivery. J Control Release. 192:262–270. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Bonomi A, Sordi V, Dugnani E, Ceserani V,
Dossena M, Coccè V, Cavicchini L, Ciusani E, Bondiolotti G, Piovani
G, et al: Gemcitabine-releasing mesenchymal stromal cells inhibit
in vitro proliferation of human pancreatic carcinoma cells.
Cytotherapy. 17:1687–1695. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
van der Meel R, Fens MH, Vader P, van
Solinge WW, Eniola-Adefeso O and Schiffelers RM: Extracellular
vesicles as drug delivery systems: Lessons from the liposome field.
J Control Release. 195:72–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Clayton A, Harris CL, Court J, Mason MD
and Morgan BP: Antigen-presenting cell exosomes are protected from
complement-mediated lysis by expression of CD55 and CD59. Eur J
Immunol. 33:522–531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Gomes-da-Silva LC, Fonseca NA, Moura V,
Pedroso de Lima MC, Simões S and Moreira JN: Lipid-based
nanoparticles for siRNA delivery in cancer therapy: Paradigms and
challenges. Acc Chem Res. 45:1163–1171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Simões S, Filipe A, Faneca H, Mano M,
Penacho N, Düzgünes N and de Lima MP: Cationic liposomes for gene
delivery. Expert Opin Drug Deliv. 2:237–254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein alpha
(SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Mendt M, Kamerkar S, Sugimoto H, McAndrews
KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, et al:
Generation and testing of clinical-grade exosomes for pancreatic
cancer. JCI insight. 3:e992632018. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Bardol T, Dujon AM, Taly V, Dunyach-Remy
C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L,
Canivet C, et al: Early detection of pancreatic cancer by liquid
biopsy ‘PANLIPSY’: A french nation-wide study project. BMC Cancer.
24:7092024. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Wei MY, Shi S, Liang C, Meng QC, Hua J,
Zhang YY, Liu J, Zhang B, Xu J and Yu XJ: The microbiota and
microbiome in pancreatic cancer: More influential than expected.
Mol Cancer. 18:972019. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Riquelme E, Zhang Y, Zhang L, Montiel M,
Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et
al: Tumor microbiome diversity and composition influence pancreatic
cancer outcomes. Cell. 178:795–806.e12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Zhang X, Liu Q, Liao Q and Zhao Y:
Pancreatic cancer, gut microbiota, and therapeutic efficacy. J
Cancer. 11:2749–2758. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Jiang Z, Mou Y, Wang H, Li L, Jin T, Wang
H, Liu M and Jin W: Causal effect between gut microbiota and
pancreatic cancer: A two-sample Mendelian randomization study. BMC
Cancer. 23:10912023. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Kartal E, Schmidt TSB, Molina-Montes E,
Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar
Alhamwe B, Alves RJ, Carrato A, et al: A faecal microbiota
signature with high specificity for pancreatic cancer. Gut.
71:1359–1372. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
McAllister F, Khan MAW, Helmink B and
Wargo JA: The Tumor microbiome in pancreatic cancer: Bacteria and
beyond. Cancer Cell. 36:577–579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Kabwe M, Dashper S and Tucci J: The
Microbiome in pancreatic cancer-implications for diagnosis and
precision bacteriophage therapy for this low survival disease.
Front Cell Infect Microbiol. 12:8712932022. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Chow YC, Yam HC, Gunasekaran B, Lai WY, Wo
WY, Agarwal T, Ong YY, Cheong SL and Tan SA: Implications of
Porphyromonas gingivalis peptidyl arginine deiminase and
gingipain R in human health and diseases. Front Cell Infect
Microbiol. 12:9876832022. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Maekawa T, Fukaya R, Takamatsu S, Itoyama
S, Fukuoka T, Yamada M, Hata T, Nagaoka S, Kawamoto K, Eguchi H, et
al: Possible involvement of Enterococcus infection in the
pathogenesis of chronic pancreatitis and cancer. Biochem Biophys
Res Commun. 506:962–969. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Zhou X, Xie F, Wang L, Zhang L, Zhang S,
Fang M and Zhou F: The function and clinical application of
extracellular vesicles in innate immune regulation. Cell Mol
Immunol. 17:323–334. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Lai RC, Yeo RW, Tan KH and Lim SK:
Exosomes for drug delivery-a novel application for the mesenchymal
stem cell. Biotechnol Adv. 31:543–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Otsuka M and Kotani A: Recent advances in
extracellular vesicles in gastrointestinal cancer and lymphoma.
Cancer Sci. 114:2230–2237. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Vosough P, Khatami SH, Hashemloo A,
Tajbakhsh A, Karimi-Fard F, Taghvimi S, Taheri-Anganeh M, Soltani
Fard E, Savardashtaki A and Movahedpour A: Exosomal lncRNAs in
gastrointestinal cancer. Clin Chim Acta. 540:1172162023. View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Tang XH, Guo T, Gao XY, Wu XL, Xing XF, Ji
JF and Li ZY: Exosome-derived noncoding RNAs in gastric cancer:
Functions and clinical applications. Mol Cancer. 20:992021.
View Article : Google Scholar : PubMed/NCBI
|
